BHLHE40 and nonpapillary renal cell carcinoma: In the DepMap cohort, approximately half of the VHL mutant ccRCC lines are sensitive to BHLHE40 KO, and interestingly, this includes all the SMARCB1 mutant lines (Figure 5F).